These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 488521)

  • 1. Experience with sustained-release oxprenolol (slow trasicor) in the management of hypertension in general practice.
    Forrest WA
    J Int Med Res; 1979; 7(4):318-23. PubMed ID: 488521
    [No Abstract]   [Full Text] [Related]  

  • 2. Slow-Trasicor (sustained-release oxprenolol hydrochloride 160 mg) in the treatment of essential hypertension: a multicentre evaluation of 4,400 patients.
    Forrest WA
    Br J Clin Pract; 1977 Nov; 31(11):181-6. PubMed ID: 339937
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of oxprenolol and methyldopa in hypertension. A within-patient double-blind trial.
    Barritt DW; Marshall AJ; Heaton S
    Lancet; 1976 Mar; 1(7958):503-5. PubMed ID: 55780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trasicor versus methyldopa in Pakistani hypertensive patients: a comparative study of efficacy and tolerability.
    Nasir ; Burke T
    J Pak Med Assoc; 1981 Aug; 31(8):172-7. PubMed ID: 6793746
    [No Abstract]   [Full Text] [Related]  

  • 5. Oxprenolol in hypertension: a report on 2,770 patients in general practice originally treated with methyldopa.
    Forrest WA
    Scott Med J; 1976 Jan; 21(1):28-30. PubMed ID: 1257736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of slow Trasicor (oxprenolol 160 mg) and Trasidrex (oxprenolol 160 mg and cyclopenthiazide 0.25 mg) in the treatment of hypertension in general practice.
    Elsdon-Dew RW; Holden E
    J Int Med Res; 1981; 9(5):315-8. PubMed ID: 7028531
    [No Abstract]   [Full Text] [Related]  

  • 7. Single-dose pharmacokinetic and pharmacodynamic comparison of polymer-matrix (Slow Trasicor) and Oros dosage forms of oxprenolol in healthy volunteers.
    Bennett PN; Bennett J; Bradbrook I; Francis J; John VA; Rogers H; Turner P; Warrington SJ
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):171S-175S. PubMed ID: 4005119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of slow release oxprenolol with conventional oxprenolol in the treatment of hypertension.
    Resnekov EB; Havard CW
    Eur J Clin Pharmacol; 1978 Nov; 14(2):77-81. PubMed ID: 363434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the duration of action of pindolol and slow release oxprenolol in healthy volunteers.
    Aellig WH
    Eur J Clin Pharmacol; 1978 Nov; 14(3):167-9. PubMed ID: 729611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of a slow release formulation of oxprenolol with conventional oxprenolol in the treatment of hypertension.
    O'Brien KP; Stephens EJ
    N Z Med J; 1976 Aug; 84(570):142-4. PubMed ID: 1069924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of clinical effects of propranolol (Inderal) with once daily slow-release oxprenolol (Slow Trasicor) in angina pectoris.
    Majid PA; de Feijter PJ; Wardeh R; van der Wall EE; Roos JP
    J Int Med Res; 1979; 7(3):194-200. PubMed ID: 378729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicentre evaluation of sustained release oxprenolol in the management of hypertension in hospital out-patient practice.
    Forrest WA
    J Int Med Res; 1978; 6(2):136-40. PubMed ID: 631415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of a slow-release formulation of oxprenolol with conventional oxprenolol in the treatment of hypertension.
    O'Brien KP; Stephens EJ
    Clin Sci Mol Med Suppl; 1976 Dec; 3():559s-561s. PubMed ID: 1071681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of oxprenolol vs methyldopa as second-line antihypertensive agents in the elderly.
    Traub YM
    Arch Intern Med; 1988 Jan; 148(1):77-80. PubMed ID: 3276279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparison of the effects of oxprenolol and nifedipine on blood pressure at rest and during physical exercise in essential hypertension].
    Gambini G; Pizzuti C; Valori C
    Clin Ter; 1988 Feb; 124(3):203-10. PubMed ID: 2974332
    [No Abstract]   [Full Text] [Related]  

  • 16. [Multicenter study of the efficacy of 3 antihypertensive regimens: captopril + hydrochlorothiazide, oxprenolol + hydrochlorothiazide, and alphamethyldopa + hydrochlorothiazide].
    Ocón J; Oliván J; Garrido Peralta M; Ruilope L; Rodicio JL; Seco Vasco J; Rodríguez Alvarez J; Gras X
    Med Clin (Barc); 1985 Nov; 85(15):617-21. PubMed ID: 3908851
    [No Abstract]   [Full Text] [Related]  

  • 17. A multiple dose comparative study of the pharmacodynamic and pharmacokinetic behaviour of polymer-matrix and Oros dosage forms of oxprenolol in healthy volunteers.
    Woods KL; Jack DB; Kendall MJ; Halsey A; O'Donnell ML; Warrington SJ; John VA
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):177S-184S. PubMed ID: 4005120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experience with a slow-release formulation of oxprenolol.
    Waal-Manning HJ; Spears GF
    N Z Med J; 1978 Apr; 87(609):245-6. PubMed ID: 275650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can once daily dosage be effective in the treatment of hypertension throughout 24 hours? A controlled evaluation of sustained release oxprenolol.
    Volan GN; Rogers HJ; House F
    Br J Clin Pharmacol; 1979 Jul; 8(1):86-9. PubMed ID: 399593
    [No Abstract]   [Full Text] [Related]  

  • 20. A multicentre study examining the substitution of Trasidrex for the free combination of Slow-Trasicor and Navidrex-K.
    Ebbutt AF; Elsdon-Dew RW
    J Int Med Res; 1979; 7(6):524-7. PubMed ID: 520655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.